ArticleMolecular biology reports2025
Anticancer potential of purified laccase enzyme from Trametes versicolor: specific cytotoxicity against thyroid and endometrial cancer cells.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Trametes versicolor laccase induces apoptosis and DNA damage in colorectal cancer via reactive oxygen species-mediated signaling disruption.Molecular biology reports · 2026Article
- Analysis of the ERG25 gene family based on the whole-genome sequence in Trametes versicolor and its response to light stress.Scientific reports · 2026Article
- Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Bacterial laccases for green remediation of contaminants of emerging concern: from molecular cloning to metagenomic and computational insights.Biodegradation · 2026Review
- Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect.Blood and lymphatic cancer : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCancer is one of the leading causes of death worldwide, highlighting the need to develop novel therapeutic strategies that are more effective and have fewer side effects than conventional treatments. Enzymatic cancer therapy is a promising approach due to its high specificity and minimal toxicity. Among the various enzymes, laccase, a widely used biocatalyst, has shown significant potential for anti-cancer applications due to its proliferation inhibitory properties. METHODS AND
resultsIn this study, the enzyme laccase from Trametes versicolor was purified by three-phase partitioning and then its cytotoxic, genotoxic and apoptotic effects on thyroid cancer (TT) and endometrial cancer (Ishikawa) cell lines were investigated. Laccase exhibited IC
conclusionsOur results emphasize the specific cytotoxicity and molecular mechanisms underlying the anti-cancer effect of laccase and demonstrate that laccase is capable of selectively targeting cancer cells and causing apoptosis and DNA damage. This study demonstrates the potential of laccase as a novel enzymatic therapeutic for the treatment of thyroid and endometrial cancer and warrants further investigation into its clinical application and efficacy.
Indexed as
Identifiers
40085415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.